New PDE4 inhibitors based on pharmacophoric similarity between papaverine and tofisopam.
Frédéric J J Bihel, Hélène Justiniano, Martine Schmitt, Malik Hellal, Mohamed A Ibrahim, Claire Lugnier, Jean-Jacques Bourguignon
Laboratoire d'Innovation Thérapeutique, UMR 7200, CNRS, Université de Strasbourg, Faculté de Pharmacie, 74 route du Rhin, 67400 Illkirch Graffenstaden, France. fbihel@unistra.fr
Bioorganic & medicinal chemistry letters 2011 Nov 1Pharmacophoric comparison between papaverine and tofisopam led to identify three new series of micro- to sub-micromolar inhibitors of phosphodiesterase-4, including 7,8-dialkoxy-2,3-benzodiazepin-4-one derivatives, 7,8-dialkoxy-1,4-benzodiazepin-2-one derivatives, and dialkoxybenzophenone derivatives. Copyright © 2011 Elsevier Ltd. All rights reserved.
Citation
Frédéric J J Bihel, Hélène Justiniano, Martine Schmitt, Malik Hellal, Mohamed A Ibrahim, Claire Lugnier, Jean-Jacques Bourguignon. New PDE4 inhibitors based on pharmacophoric similarity between papaverine and tofisopam. Bioorganic & medicinal chemistry letters. 2011 Nov 1;21(21):6567-72
Mesh Tags
Substances
PMID: 21920746
View Full Text
